Development of the treatment for acute coronary syndrome by dental bacteria elimination

牙科除菌疗法治疗急性冠状动脉综合征的进展

• 批准号: 20592214
• 负责人: SASAKI Ken-Ichiro
• 金额: $ 2.66万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20592214/
• 关键词: 虚血性心臓病; 急性冠症候群; 動脈硬化; 血管内プラーク; 歯周病菌; 感染; 炎症; 歯周病治療; 免疫

In 174 patients with acute coronary syndrome (ACS), the DNA of P. gingivalis, which is a representative responsible bacterium for periodontal disease (PD), was detected in 58% of the sample including the coronary artery blood and the atherosclerotic plaque. Moreover, the activity of Gingipain, which is a protease from the bacterium, increased in the plaque. Although we speculated that the treatment of PD can prevent the protease-induced plaque rupture for ACS and thereby reduce the major adverse cardiac event, the detection of the bacterium in the sample did not influence to the event rate at 6 months after the onset of ACS in the prognosis research for average 14.8 months.

在174例急性冠状动脉综合征（ACS）患者的冠状动脉血和动脉粥样硬化斑块中，检出牙龈卟啉单胞菌（P.gingivalis）DNA的比例为58%。此外，牙龈蛋白酶（一种来自细菌的蛋白酶）的活性在牙菌斑中增加。虽然我们推测PD治疗可以预防ACS的蛋白酶诱导的斑块破裂，从而减少主要不良心脏事件，但在平均14.8个月的预后研究中，样本中细菌的检测对ACS发病后6个月的事件发生率没有影响。

项目成果

ホームページ等。

主页等